Fresenius Amends Humacyte Stake: 13D/A Filed 3/24/26

TL;DR

**Fresenius just updated its ownership stake in Humacyte, watch for potential stock movement.**

AI Summary

Fresenius Medical Care Holdings Inc. /NY/ filed a SCHEDULE 13D/A on March 24, 2026, indicating an amendment to their beneficial ownership in Humacyte, Inc. This filing updates previous disclosures about Fresenius's stake in Humacyte, a company specializing in biological products. This matters to investors because changes in ownership by large institutional holders like Fresenius can signal their confidence or concerns about Humacyte's future prospects and potentially influence the stock price.

Why It Matters

This filing updates the public record on a significant investor's position in Humacyte, which can impact market perception and trading activity for Humacyte's stock.

Risk Assessment

Risk Level: medium — While an amendment isn't inherently risky, the underlying change in ownership could signal a shift in a major investor's sentiment, which carries moderate risk for current shareholders.

Analyst Insight

An investor should investigate the details of the amended Schedule 13D/A to understand the specific changes in Fresenius's beneficial ownership of Humacyte, as this could indicate a strategic shift or a change in investment thesis, potentially influencing Humacyte's stock performance.

Key Players & Entities

• Fresenius Medical Care Holdings Inc. /NY/ (company) — the entity filing the SCHEDULE 13D/A
• Humacyte, Inc. (company) — the subject company of the SCHEDULE 13D/A filing
• March 24, 2026 (date) — the filing date of the SCHEDULE 13D/A
• 0001104659-26-033489 (other) — SEC Accession No. for the filing

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities

Filing Documents

• primary_doc.html (SCHEDULE 13D/A)
• primary_doc.xml (SCHEDULE 13D/A) — 9KB
• 0001104659-26-033489.txt ( ) — 11KB

Security and Issuer

Item 1. Security and Issuer (a) Title of Class of Securities: Common Stock, par value $0.0001 per share (b) Name of Issuer: HUMACYTE, INC. (c) Address of Issuer's Principal Executive Offices: 2525 East North Carolina Highway 54, Durham, NORTH CAROLINA , 27713.

Comment

Item 1 Comment: This Amendment No. 7 amends certain information contained in the Schedule 13D originally filed by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") on September 2, 2021, as previously amended by Amendment No. 1 filed December 1, 2023, Amendment No. 2 filed March 7, 2024, Amendment No 3 filed November 18, 2024, Amendment No 4 filed May 22, 2025, Amendment No 5 filed solely by FME AG on October 16 2025 and Amendment No. 6 filed by FME AG and FMCH on January 9;2026 (as so amended, the "Schedule 13D"), with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 7 does not modify any of the information previously reported on the Schedule 13D.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a) On the date of this Schedule 13D (Amendment No. 7), FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock, constituting approximately 8.4% of the Issuer's outstanding voting shares. Such percentage ownership is calculated by reference to 218,453,511 shares outstanding as of March 20, 2026, comprising (i) 187,727,321 shares outstanding as shown on the cover page of the Issuer's Form 10-Q filed November 12, 2025 plus (ii) 5,725,190 shares issued on December 15, 2025, as reported in the Issuer's Form 8-K filed that date, plus (iii) 25,000,000 shares issued on March 20, 2026, as reported by the Issuer in its Form 8-K report filed on March 19, 2026. All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH. Such 18,312,735 shares of Common Stock exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement described in the initial Schedule 13D, and FME AG and FMCH disclaim any present beneficial ownership of any such additional shares. (b) As the record owner of the 18,312,735 shares of Common Stock reported in this Schedule 13D (Amendment No 7), FMCH possesses voting and dispositive power over such shares. FME AG is the indirect sole shareholder of FMCH and may be deemed to be a beneficial owner of such shares. (c) The decrease in the percentage beneficial ownership reported herein from 9.5%, as reported in Schedule 13D (Amendment No. 6) to 8.4%, as reported herein, results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 6 to this Schedule 13D, as described in Item 5(a). Neither FME AG nor FMCH has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of their initial Schedule 13D in September 2021.     SIGNATURE     After reasonable inquiry and to the best of my knowledge and bel

View Full Filing

View this filing on SEC EDGAR